BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 27260521)

  • 1. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.
    Afshar-Oromieh A; Hetzheim H; Kübler W; Kratochwil C; Giesel FL; Hope TA; Eder M; Eisenhut M; Kopka K; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1611-20. PubMed ID: 27260521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Internal Dosimetry of 18 F-PSMA-1007 and 68 Ga-PSMA-11-HBED-CC.
    Sharma P; Watts A; Singh H
    Clin Nucl Med; 2022 Nov; 47(11):948-953. PubMed ID: 35961365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
    Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
    Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
    J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
    Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Early and Late [
    Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
    Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.
    Herrmann K; Bluemel C; Weineisen M; Schottelius M; Wester HJ; Czernin J; Eberlein U; Beykan S; Lapa C; Riedmiller H; Krebs M; Kropf S; Schirbel A; Buck AK; Lassmann M
    J Nucl Med; 2015 Jun; 56(6):855-61. PubMed ID: 25883128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early dynamic imaging in
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; Warwitz B; Scarpa L; Roig LG; Kendler D; von Guggenberg E; Bektic J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):765-775. PubMed ID: 27900519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of radiation dosimetry for
    Green MA; Eitel JA; Fletcher JW; Mathias CJ; Tann MA; Gardner T; Koch MO; Territo W; Polson H; Hutchins GD
    Nucl Med Biol; 2017 Mar; 46():32-35. PubMed ID: 28012435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
    Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
    J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
    [No Abstract]   [Full Text] [Related]  

  • 14. Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [
    Doot RK; Young AJ; Daube-Witherspoon ME; Alexoff D; Labban KJ; Lee H; Wu Z; Zha Z; Choi SR; Ploessl KH; Schubert EK; Lee H; Zhu L; Reddin JS; Karp JS; Kung H; Pryma DA
    Nucl Med Biol; 2020; 86-87():1-8. PubMed ID: 32361089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
    Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
    Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S
    Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
    Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
    Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
    Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary Evaluation of
    Lee H; Scheuermann JS; Young AJ; Doot RK; Daube-Witherspoon ME; Schubert EK; Fillare MA; Alexoff D; Karp JS; Kung HF; Pryma DA
    Mol Imaging Biol; 2022 Oct; 24(5):710-720. PubMed ID: 35349040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.